Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
ELVN Stock Chart & Stats
$26.72
$0.01(0.04%)
At close: 4:00 PM EST
$26.72
$0.01(0.04%)
Day’s Range― - ―
52-Week Range$13.30 - $30.22
Previous CloseN/A
Volume37.78K
Average Volume (3M)1.31M
Market Cap
$1.59B
Enterprise Value$1.45B
Total Cash (Recent Filing)$477.56M
Total Debt (Recent Filing)$387.00K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 12, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding59,347,317
10 Day Avg. Volume729,013
30 Day Avg. Volume1,307,351
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)3.42
Price to Sales (P/S)0.00
P/FCF Ratio-14.46
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.54
Forecast
1Y Price Target
$37.00Price Target Upside38.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.02
Revenue Forecast (FY)$7.14K
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy In Refractory PatientsEarly clinical data demonstrated robust and durable molecular responses in heavily pretreated chronic myeloid leukemia patients, including those who had failed multiple prior therapies.
Combination Therapy PotentialPreclinical and clinical evidence that ELVN-001 and asciminib effectively suppress resistant clones supports a combination strategy to address diverse resistance mutations.
Mechanism Of ActionELVN-001 inhibits an ATP-binding pocket distinct from competitors, enabling treatment of patients who were refractory to therapies that bind the alternate pocket.
Bears Say
Competitive BenchmarkingA competing BCRABL inhibitor reported higher early response rates, creating a performance benchmark that could pressure ELVN-001's market positioning.
Development And Regulatory RiskUncertainty about the final Phase 3 design and the inherent risk of clinical setbacks increase the chance that ELVN-001 may face delays or fail to reach a registration-enabling outcome.
Enrollment CompetitionA rival program expected to start a pivotal trial could slow enrollment for ELVN-001's pivotal study, risking delays to key development milestones.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $13.30 and its highest was $30.22 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $1.59B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 22 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.113.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 59,347,317 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went down -0.148%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.00 (38.47% Upside)
$37.00 (38.47% Upside)
Blogger Sentiment
Neutral
ELVN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.27%
12-Months-Change
Fundamentals
Return on Equity
-25.43%
Trailing 12-Months
Asset Growth
60.72%
Trailing 12-Months
Company Description
Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$37.00
▲(38.47% Upside)
Technical Analysis
Sarepta Therapeutics
―
Viridian Therapeutics
―
―
Intellia Therapeutics
―
AbCellera Biologics
―